Inmune Bio director Clark Ronnie Duane received 100,000 derivative securities on September 15, establishing a resulting holding of 100,000 securities. The transaction matters to investors because it represents 100.0% of his resulting derivative-securities position and marks a new insider position at the biotechnology company.

Key Highlights

  • Clark Ronnie Duane received 100,000 derivative securities from Inmune Bio on September 15, 2026.
  • The director’s resulting holding stood at 100,000 derivative securities.
  • The award represented 100.0% of Clark Ronnie Duane’s resulting derivative-securities total.

Inmune Bio, Inc. (NASDAQ: INMB), a biotechnology company, awarded director Clark Ronnie Duane 100,000 derivative securities on September 15, 2026. Clark’s post-transaction holding was 100,000 derivative securities in Inmune Bio. The award itself accounted for 100.0% of that resulting total. Clark reported a new insider position at Inmune Bio. The recorded award date was September 15, 2026.